[{"id":"c9fa59c0-ee9b-4c5f-baf7-8f04f47fe653","acronym":"","url":"https://clinicaltrials.gov/study/NCT05630794","created_at":"2022-11-30T18:57:52.049Z","updated_at":"2025-02-25T13:41:21.187Z","phase":"Phase 1","brief_title":"Testing ONC201 to Prevent Colorectal Cancer","source_id_and_acronym":"NCT05630794","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL","pipe":"","alterations":" ","tags":["BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/30/2025","start_date":" 03/30/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-02-21"},{"id":"fb5a3d64-2b8f-44c4-84f0-e927e52ab2a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04939051","created_at":"2024-02-29T18:31:43.001Z","updated_at":"2025-02-25T13:35:51.854Z","phase":"Phase 2","brief_title":"Obeticholic Acid for Prevention in Barrett's Esophagus","source_id_and_acronym":"NCT04939051","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FGF19 • SOX2 • CASP3 • FGF • CDX2","pipe":"","alterations":" ","tags":["FGF19 • SOX2 • CASP3 • FGF • CDX2"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/03/2024","start_date":" 01/03/2024","primary_txt":" Primary completion: 09/29/2025","primary_completion_date":" 09/29/2025","study_txt":" Completion: 09/29/2026","study_completion_date":" 09/29/2026","last_update_posted":"2025-02-21"},{"id":"58cd7400-0401-4fe2-920b-51c73459a5ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT06796634","created_at":"2025-02-25T18:01:35.518Z","updated_at":"2025-02-25T18:01:35.518Z","phase":"","brief_title":"Effects of Cold Atmospheric Plasma (CAP) on Peritoneal Tumor Tissue","source_id_and_acronym":"NCT06796634","lead_sponsor":"University Hospital, Ghent","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"],"overall_status":"Recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 08/21/2024","start_date":" 08/21/2024","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-01-28"},{"id":"1631cb9a-3bed-4607-9043-c30f2e5af7df","acronym":"ZE50-0134-0002","url":"https://clinicaltrials.gov/study/NCT06708897","created_at":"2025-02-26T11:42:54.327Z","updated_at":"2025-02-26T11:42:54.327Z","phase":"Phase 1","brief_title":"A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas","source_id_and_acronym":"NCT06708897 - ZE50-0134-0002","lead_sponsor":"Eilean Therapeutics","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-11-27"},{"id":"fe6e795f-22fd-4cd7-b9e7-1f7eb8efecb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06700070","created_at":"2025-02-26T12:47:00.042Z","updated_at":"2025-02-26T12:47:00.042Z","phase":"Phase 1","brief_title":"A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors","source_id_and_acronym":"NCT06700070","lead_sponsor":"Pure Biologics S.A.","biomarkers":" TNFA • CASP3 • GZMB • CD86","pipe":"","alterations":" ","tags":["TNFA • CASP3 • GZMB • CD86"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-11-21"},{"id":"ef502e78-36b6-4881-b791-586dbda2fa9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04379999","created_at":"2021-01-18T21:09:15.617Z","updated_at":"2024-07-02T16:34:26.352Z","phase":"Phase 1","brief_title":"Atorvastatin ± Aspirin in Lynch Syndrome Syndrome","source_id_and_acronym":"NCT04379999","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM • CASP3","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-13"},{"id":"7f306611-7670-46f5-9d82-2776f52be9ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633239","created_at":"2022-11-25T17:57:43.239Z","updated_at":"2024-07-02T16:34:37.807Z","phase":"Phase 1","brief_title":"Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer","source_id_and_acronym":"NCT04633239","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • HRD • CCNE1 • BRCA • CASP3","pipe":" | ","alterations":" HRD","tags":["BRCA1 • HRD • CCNE1 • BRCA • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/02/2021","start_date":" 07/02/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-06"},{"id":"5281d885-db71-4720-b9bf-1c0b248f2e5b","acronym":"NCI-2022-04099","url":"https://clinicaltrials.gov/study/NCT05372614","created_at":"2022-05-13T12:54:23.489Z","updated_at":"2024-07-02T16:34:58.772Z","phase":"Phase 1","brief_title":"Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene","source_id_and_acronym":"NCT05372614 - NCI-2022-04099","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • CD4 • CASP3","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • HER-2 H878Y • HER-2 L866M • HER-2 A775 • HER-2 G309A • HER-2 P780-Y781insGSP • HER-2 R678Q • HER-2 R896C • HER-2 T862A • HER-2 YVMA","tags":["HER-2 • CD4 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • HER-2 H878Y • HER-2 L866M • HER-2 A775 • HER-2 G309A • HER-2 P780-Y781insGSP • HER-2 R678Q • HER-2 R896C • HER-2 T862A • HER-2 YVMA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/05/2022","start_date":" 10/05/2022","primary_txt":" Primary completion: 06/17/2024","primary_completion_date":" 06/17/2024","study_txt":" Completion: 06/17/2024","study_completion_date":" 06/17/2024","last_update_posted":"2024-06-05"},{"id":"0c2a810f-7b1e-4ebc-bfd5-e19f2213781b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06378398","created_at":"2024-04-22T23:49:34.896Z","updated_at":"2024-07-02T16:34:59.215Z","phase":"Phase 1","brief_title":"A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy","source_id_and_acronym":"NCT06378398","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e omeprazole"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-06-04"},{"id":"0ddf2dab-b38d-4054-a616-48669cd75157","acronym":"","url":"https://clinicaltrials.gov/study/NCT02143401","created_at":"2021-01-18T09:57:19.810Z","updated_at":"2024-07-02T16:35:01.909Z","phase":"Phase 1","brief_title":"Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT02143401","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MCL1 • AFP • CASP3","pipe":" | ","alterations":" MCL1 expression","tags":["MCL1 • AFP • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 11/07/2014","start_date":" 11/07/2014","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 05/20/2025","study_completion_date":" 05/20/2025","last_update_posted":"2024-05-22"},{"id":"9d91719c-a4f8-489a-a4f8-f503e0f382e7","acronym":"PBL-0405-01","url":"https://clinicaltrials.gov/study/NCT06273852","created_at":"2024-02-23T16:26:42.227Z","updated_at":"2024-07-02T16:35:03.110Z","phase":"Phase 1","brief_title":"A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors","source_id_and_acronym":"NCT06273852 - PBL-0405-01","lead_sponsor":"Pure Biologics S.A.","biomarkers":" ROR1 • TNFA • CASP3 • GZMB • CD86","pipe":"","alterations":" ","tags":["ROR1 • TNFA • CASP3 • GZMB • CD86"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/29/2024","start_date":" 04/29/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-17"},{"id":"d7d6598c-31e5-4bc3-b406-5e9ff144fe1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03834740","created_at":"2021-01-18T18:56:01.539Z","updated_at":"2024-07-02T16:35:04.374Z","phase":"Phase 1","brief_title":"A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection","source_id_and_acronym":"NCT03834740","lead_sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","biomarkers":" PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression","tags":["PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 02/18/2022","primary_completion_date":" 02/18/2022","study_txt":" Completion: 02/18/2022","study_completion_date":" 02/18/2022","last_update_posted":"2024-05-10"},{"id":"b8813467-068d-4010-8e2e-a3efe97a80e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02379377","created_at":"2021-01-18T11:20:05.224Z","updated_at":"2024-07-02T16:35:05.006Z","phase":"Phase 1","brief_title":"18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant","source_id_and_acronym":"NCT02379377","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD163 • CASP3 • CD86","pipe":"","alterations":" ","tags":["CD163 • CASP3 • CD86"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 02/15/2022","start_date":" 02/15/2022","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-05-08"},{"id":"37cf995c-7407-44e4-a1b3-63bf8d55111e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05385705","created_at":"2024-04-23T19:55:12.828Z","updated_at":"2025-02-25T12:28:47.565Z","phase":"Phase 1","brief_title":"A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020","source_id_and_acronym":"NCT05385705","lead_sponsor":"Vall d'Hebron Institute of Oncology","biomarkers":" CD8 • CD4 • NCAM1 • CASP3","pipe":"","alterations":" ","tags":["CD8 • CD4 • NCAM1 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/11/2022","start_date":" 05/11/2022","primary_txt":" Primary completion: 09/11/2026","primary_completion_date":" 09/11/2026","study_txt":" Completion: 04/11/2027","study_completion_date":" 04/11/2027","last_update_posted":"2024-04-23"},{"id":"39769fed-659c-4bfe-8a22-cc44cf784049","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541108","created_at":"2021-01-18T21:43:38.590Z","updated_at":"2024-07-02T16:35:08.887Z","phase":"Phase 1","brief_title":"Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies","source_id_and_acronym":"NCT04541108","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-04-18"},{"id":"8626d796-d31d-4f11-a4ab-8ea3dce4cf77","acronym":"","url":"https://clinicaltrials.gov/study/NCT03725436","created_at":"2021-01-18T18:15:21.875Z","updated_at":"2024-07-02T16:35:08.781Z","phase":"Phase 1","brief_title":"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors","source_id_and_acronym":"NCT03725436","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A","pipe":" | ","alterations":" ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification","tags":["HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • sulanemadlin (ALRN-6924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-04-18"},{"id":"0aa5776e-fde4-461e-99ec-adb77df22f25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03232138","created_at":"2021-01-18T15:56:57.786Z","updated_at":"2024-07-02T16:35:11.229Z","phase":"Phase 2","brief_title":"Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers","source_id_and_acronym":"NCT03232138","lead_sponsor":"Jian-Min Yuan, MD","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 01/25/2018","start_date":" 01/25/2018","primary_txt":" Primary completion: 02/17/2023","primary_completion_date":" 02/17/2023","study_txt":" Completion: 02/17/2023","study_completion_date":" 02/17/2023","last_update_posted":"2024-04-05"},{"id":"f1142c88-f86a-4438-ad44-8930d0b16ed7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04559685","created_at":"2021-01-18T21:47:35.667Z","updated_at":"2024-07-02T16:35:12.507Z","phase":"Phase 1","brief_title":"Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT04559685","lead_sponsor":"Nader Sanai","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALA sonodynamic therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/15/2021","start_date":" 03/15/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-03-27"},{"id":"06d625a6-cf6f-4d0a-9c63-1adbf21e5730","acronym":"","url":"https://clinicaltrials.gov/study/NCT01364051","created_at":"2024-03-13T08:33:16.360Z","updated_at":"2024-07-02T16:35:15.340Z","phase":"Phase 1","brief_title":"Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies","source_id_and_acronym":"NCT01364051","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 05/25/2011","start_date":" 05/25/2011","primary_txt":" Primary completion: 06/06/2019","primary_completion_date":" 06/06/2019","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-03-11"},{"id":"46c4dafa-648c-4f9b-8154-30165bb2495f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01849146","created_at":"2024-03-06T15:37:16.511Z","updated_at":"2024-07-02T16:35:16.074Z","phase":"Phase 1","brief_title":"Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma","source_id_and_acronym":"NCT01849146","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • MGMT • CASP3 • WEE1","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • MGMT • CASP3 • WEE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • adavosertib (AZD1775)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/19/2013","start_date":" 08/19/2013","primary_txt":" Primary completion: 07/29/2021","primary_completion_date":" 07/29/2021","study_txt":" Completion: 03/04/2025","study_completion_date":" 03/04/2025","last_update_posted":"2024-03-06"},{"id":"f412b2c8-e0f1-4eb7-8ad6-30e34f96ac6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01542021","created_at":"2021-01-18T06:31:02.146Z","updated_at":"2024-07-02T16:35:17.074Z","phase":"","brief_title":"Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer","source_id_and_acronym":"NCT01542021","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Firmagon (degarelix)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-02-29"},{"id":"e8d11d0d-22f1-48ae-b470-5a7c61faf861","acronym":"","url":"https://clinicaltrials.gov/study/NCT06195371","created_at":"2024-01-08T16:17:50.082Z","updated_at":"2024-07-02T16:35:17.322Z","phase":"","brief_title":"Impact of CASP3 Gene in Chemoresistance","source_id_and_acronym":"NCT06195371","lead_sponsor":"Gehad Salah El-Din shaker","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-02-28"},{"id":"fd1666a8-c3ef-43e6-9207-5e19e3282d91","acronym":"NIREC","url":"https://clinicaltrials.gov/study/NCT05289648","created_at":"2022-03-21T19:56:04.999Z","updated_at":"2024-07-02T16:35:21.231Z","phase":"Phase 1","brief_title":"Niraparib in High-grade Endometrial Cancer Trial","source_id_and_acronym":"NCT05289648 - NIREC","lead_sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","biomarkers":" TP53 • CCND1 • CASP3 • CDKN1A","pipe":" | ","alterations":" CCND1 expression","tags":["TP53 • CCND1 • CASP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2024-02-01"},{"id":"2081d67d-68ba-4944-9cbd-65ba437e972d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05627232","created_at":"2024-01-05T19:19:11.024Z","updated_at":"2024-07-02T16:35:24.396Z","phase":"Phase 1","brief_title":"Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05627232","lead_sponsor":"Thomas Jefferson University","biomarkers":" CASP3 • ANXA5","pipe":"","alterations":" ","tags":["CASP3 • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/28/2023","start_date":" 08/28/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-01-05"}]